$1.28 Billion is the total value of Camber Capital Management LP's 39 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 90.9% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SPY | New | SPDR S&P 500 ETF TRput | $233,763,000 | – | 1,250,000 | +100.0% | 18.32% | – |
THC | Buy | TENET HEALTHCARE CORP | $72,777,000 | +57.1% | 1,700,000 | +54.5% | 5.70% | +39.5% |
DGX | Buy | QUEST DIAGNOSTICS INC | $63,712,000 | +48.7% | 1,100,000 | +37.5% | 4.99% | +32.2% |
CYH | Buy | COMMUNITY HEALTH SYS INC | $48,962,000 | +149.4% | 1,250,000 | +150.0% | 3.84% | +121.5% |
5100PS | Buy | VOLCANO CORPORATION | $48,289,000 | -6.0% | 2,450,000 | +4.3% | 3.78% | -16.4% |
HAE | New | HAEMONETICS CORP | $39,173,000 | – | 1,202,000 | +100.0% | 3.07% | – |
LH | New | LABORATORY CORP AMER HLDGS | $36,829,000 | – | 375,000 | +100.0% | 2.89% | – |
UAM | Buy | UNIVERSAL AMERN CORP NEW | $29,540,000 | +61.9% | 4,178,259 | +67.1% | 2.32% | +43.8% |
HRC | New | HILL ROM HLDGS INC | $23,124,000 | – | 600,000 | +100.0% | 1.81% | – |
ABT | New | ABBOTT LABS | $23,106,000 | – | 600,000 | +100.0% | 1.81% | – |
KERX | New | KERYX BIOPHARMACEUTICALS INC | $21,300,000 | – | 1,250,000 | +100.0% | 1.67% | – |
AMRN | Buy | AMARIN CORP PLCsponsor adr new | $19,910,000 | +18.9% | 11,000,000 | +29.4% | 1.56% | +5.6% |
GHDX | New | GENOMIC HEALTH INC | $19,755,000 | – | 750,000 | +100.0% | 1.55% | – |
BLUE | Buy | BLUEBIRD BIO INC | $16,075,000 | +270.3% | 706,900 | +241.7% | 1.26% | +229.0% |
FURX | New | FURIEX PHARMACEUTICALS INC | $13,050,000 | – | 150,000 | +100.0% | 1.02% | – |
TRNX | Buy | TORNIER N V | $13,022,000 | +177.2% | 613,655 | +145.5% | 1.02% | +146.6% |
GERN | Buy | GERON CORP | $9,823,000 | +38.2% | 4,700,000 | +213.3% | 0.77% | +22.8% |
RVNC | New | REVANCE THERAPEUTICS INC | $9,450,000 | – | 300,000 | +100.0% | 0.74% | – |
TRGT | Buy | TARGACEPT INC | $7,410,000 | +864.8% | 1,560,000 | +742.8% | 0.58% | +754.4% |
SQNM | New | SEQUENOM INC | $7,133,000 | – | 2,911,520 | +100.0% | 0.56% | – |
BIOL | Buy | BIOLASE INC | $6,543,000 | -14.4% | 2,715,119 | +0.5% | 0.51% | -23.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
MYLAN NV | 21 | Q3 2020 | 10.1% |
AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
Solid Biosciences Inc. | December 12, 2022 | ? | ? |
AVROBIO, Inc. | February 14, 2022 | ? | ? |
COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
Change Healthcare Inc. | February 16, 2021 | ? | ? |
GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
13F-HR | 2023-11-14 |
SC 13G | 2023-10-30 |
13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.